GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurogene Inc (NAS:NGNE) » Definitions » Additional Paid-In Capital

Neurogene (Neurogene) Additional Paid-In Capital : $374.85 Mil(As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neurogene Additional Paid-In Capital?


Neurogene's quarterly additional paid-in capital increased from Sep. 2023 ($6.33 Mil) to Dec. 2023 ($373.18 Mil) and increased from Dec. 2023 ($373.18 Mil) to Mar. 2024 ($374.85 Mil).

Neurogene's annual additional paid-in capital increased from Dec. 2021 ($3.77 Mil) to Dec. 2022 ($5.10 Mil) and increased from Dec. 2022 ($5.10 Mil) to Dec. 2023 ($373.18 Mil).


Neurogene Additional Paid-In Capital Historical Data

The historical data trend for Neurogene's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurogene Additional Paid-In Capital Chart

Neurogene Annual Data
Trend Dec21 Dec22 Dec23
Additional Paid-In Capital
3.77 5.10 373.18

Neurogene Quarterly Data
Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial - 5.91 6.33 373.18 374.85

Neurogene Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Neurogene Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Neurogene's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurogene (Neurogene) Business Description

Industry
Comparable Companies
Traded in Other Exchanges
N/A
Address
535 W 24th Street, 5th Floor, New York, NY, USA, 10011
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.

Neurogene (Neurogene) Headlines